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To evaluate the eﬀectiveness of Uncaria tomentosa in minimizing the side eﬀects of chemotherapy and improving the antioxidant
status of colorectal cancer (CRC) patients, a randomized clinical trial was conducted. Patients (43) undergoing adjuvant/palliative
chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin (FOLFOX4) were split into two groups: the UT group received
chemotherapy plus 300mg of Uncaria tomentosa daily and the C group received only FOLFOX4 and served as a control. Blood
samples were collected before each of the 6 cycles of chemotherapy, and hemograms, oxidative stress, enzymes antioxidants,
immunologic parameters, and adverse events were analyzed. The use of 300mg of Uncaria tomentosa daily during 6 cycles of
FOLFOX4 did not change the analyzed parameters, and no toxic eﬀects were observed.
1.Introduction
After histological diagnosis of colorectal cancer, the treat-
ment of advanced stages of cancer involves adjuvant or pal-
liative chemotherapy. One common treatment plan includes
the application of 5-ﬂuoruracil (5FU)/leucovorin and oxali-
platin (FOLFOX4) [1]. However, side eﬀects from this treat-
ment include severe neutropenia (grade 3 or 4 according to
Common Toxicity Criteria of the National Cancer Institute)
in 41.1% of patients [1]. Besides the cytotoxic eﬀect of the
chemotherapy, the cause of the neutropenia may be related
to oxidative stress, because high H2O2 levels may negatively
inﬂuence the proliferation and diﬀerentiation of myeloid
precursors [2]. There is a well-documented relationship
between oxidative stress and colorectal cancer. Oxidative
stress may result in both DNA damage [3] and the expansion
of neoplastic cells, because tumoral metabolic adaptations
generate high level of reactive oxygen species (ROS) [4].
Additionally, chemotherapeutic cancer treatments increase
oxidative stress levels [5], resulting in high levels of reactive
oxygen species (ROS) and damage to the lipids of the cyto-
plasmic membrane, cellular proteins, and DNA [2].
The immune status of patients, particularly CD8+ and
CD4+ Tc e l l s( T regs) levels, shows a correlation with survival.
The CD4+/CD8+ ratio of the tumor inﬁltrating lymphocytes
is signiﬁcantly associated with colorectal cancer progno-
sis [6]. Treatment with 5FU increases IFN-γ production
through the action of tumor-speciﬁc CD8+ T cells that
inﬁltrate the tumor, and it promotes T cell-dependent
antitumorresponsesinvivo[7].Again,thereisaninteraction
betweentheimmuneresponseandoxidativestress.Exposure
to reactive oxygen species (ROS) produced by activated
granulocytes and macrophages in the context of malignant
disorders causes dysfunction of T-cells and NK cells [8].
High levels of superoxide dismutase (SOD—an antioxidant
enzyme) contribute to tumor cell resistance and therapy
insensitivity and are correlated with poor outcome [9].2 Evidence-Based Complementary and Alternative Medicine
For these reasons, it is important to search for com-
plementary treatments, including phytotherapic plants, that
minimize the neutropenia associated with colon cancer
chemotherapy. Uncaria tomentosa (Ut, Cat’s claw) has an-
tioxidant properties [10] and can stimulate DNA repair
[11] and myelopoiesis [12]. Eberlin et al. [12] showed that
Ut extract promotes proliferation of myeloid precursors
through the increase in serum colony stimulating growth
factors (CSFs). Other preclinical experiments have demon-
strated the positive eﬀect of aqueous Ut extract on leukocyte
counts over a period of eight weeks in healthy animals
[13] and after ten days of doxorubicin-induced neutropenia
[14]. Given these characteristics, Ut could minimize the
undesirable eﬀects of chemotherapy and might improve the
balance between stress and antioxidants in cancer patients.
This clinical study aimed to evaluate the eﬀect of coadjuvant
treatment with Ut compared with conventional chemother-
apy for colorectal cancer. The investigation evaluated the
eﬀect of Ut on oxidative stress and its consequences in
relation to neutropenia, other hematological parameters,
immune system, safety, and side eﬀects.
2. Methods
2.1. Design and Patients. We performed a randomized inter-
ventional study of colorectal cancer patients who were sub-
mitted to chemotherapy treatment.
The study was carried out with 43 patients (26 female, 17
male) who had undergone complete resection of their col-
orectal cancer, which was of histologically scored as stage IIB,
III, or IV, and who were going to begin adjuvant/palliative
chemotherapy with FOLFOX4 at the Hospital Universit´ ario
de Santa Maria, Brazil.
Patients were randomly grouped into two groups, ac-
cording to the date of treatment start as follows: the ﬁrst
patient who agreed participating in the study was included
into UT group, the second into the C group, and successively
until the end. The UT group was treated with FOLFOX4
plus Ut, and the control group (C) received only FOLFOX4.
Patients remained on study during 6 chemotherapies cycles,
of 15 days each. The doses of medication in UT group were
as follows: Oxaliplatin, 85mg/m2 on day1; 5FU, 1g/m2 on
days 1 and 2; Leucovorin, 200mg/m2 on days 1 and 2; and
Ut (Unha de Gato Herbarium), 3 tablets daily from day 3
to day 15. The dose of Ut is similar to that used in previous
study, using 250–350mg C-MED-100, an aqueous extracts
of Ut [11]. No changes in food intake pattern had occurred
during the supplementation.
The calculation for estimating the sample size required
for a randomized clinical trial was according to Greenberg et
al. [15], with constant level of signiﬁcance (α)o f5 % ,a n d
statistical power of 90% (β 10%), using as a reference the
study of Sheng et al. [13].
The Human Ethics Committee of the Universidade
Federal de Santa Maria approved this study, and informed
consent was obtained from all participants (protocol n.
0169.0.243.000-07).
2.2. Materials. Each tablet of Unha de Gato Herbarium
contained100mgdryUt extract.Biologicalmaterialsusedin
the tablets were derived from plants in their natural habitat.
The Ut extract was prepared by ultra-turrax extraction
(Biotron, Kinematica AG) from ground bark (Centroﬂora)
using 70% ethanol (Dipalcool). The HPLC analysis of Ut dry
extract presents the content of 2.57% pentacyclic oxindole
alkaloids (POAs), which were calculated with reference to
external calibration curves of mitraphylline. The analysis of
extract showed absence of tetracyclic oxindole alkaloids in
the sample, allowing its use for therapeutic and research
purposes in accordance with U.S. Pharmacopeia.
2.3. Sample Collection. Blood was collected in citrated,
EDTA, heparin, and without anticoagulant Vacutainer tubes,
before chemotherapy and after each of the 6 cycles. CAT and
SOD activities were determined using whole blood diluted in
a 1:20 saline solution.
2.4. Biochemical Parameters. A COBAS INTEGRA system
was used for the quantitative determination of the chemical
constituents of the blood, and data were acquired using a
COBAS INTEGRA 400 plus apparatus (USA).
2.5. Carbonylation of Serum Protein. The carbonylation of
serum proteins was determined through a modiﬁcation of
the Levine method [16].
2.6. Determination of Lipid Peroxidation. Lipid peroxidation
was estimated by measuring TBARS in plasma samples
according to a modiﬁcation of the method of Jentzsch et al.
[17].
2.7. Catalase (CAT) and Superoxide Dismutase (SOD) Activi-
ties. The determination of CAT activity level was carried out
in accordance with a modiﬁcation of the method of Nelson
and Kiesow [18]. SOD activity was calculated based on the
ability to inhibit the reaction of superoxide and adrenaline,
as described by McCord and Fridovich [19].
2.8. Hemograms. Blood samples were analyzed using a
Pentraapparatus(France).Thelowestvalueswereconﬁrmed
by observation of slides using May Gr¨ unwald-Giemsa stain
and optical microscopy.
2.9. Interleukin 6 (IL-6). ELISA assays of IL-6 were carried
outaccordingtoapreviouslypublishedmethod[20]atr oom
temperature in 96-well microtitre plates (Nunc-Immuno
PlateMaxiSorp),andopticaldensities(O.D.)at490nmwere
determined using a microplate reader (Thermo Scientiﬁc
Multiskan FC, Vantaa, Finland).
2.10. Single Cell Gel Electrophoresis (Comet Assay). Alkaline
c o m e ta s s a y sw e r ep e r f o r m e da sd e s c r i b e db yS i n g he ta l .
[21]. One hundred cells (50 cells from each of the twoEvidence-Based Complementary and Alternative Medicine 3
replicate slides) were selected and analyzed. The slides were
analyzed under blind conditions by at least two diﬀerent
individuals.
2.11. CD3+,C D 4 +, and CD8+ Cells. Samples were collected
in EDTA, and analyses were performed using a three-
color ﬂuorescence-activated cell sorter (FACScalibur, Becton
Dickinson Biosciences, USA) and Multiset software (Becton
Dickinson). FITC-conjugated anti-CD4, PE conjugated anti-
CD8 and PerCp conjugated anti-CD3 were used. Immune
subpopulations were measured as a percentage of the total
number of CD3+ cells.
2.12. Adverse Events. The Common Terminology Criteria
for Adverse Events (AE) v3.0 (CTCAE) from the National
Institutes of Health/National Cancer Institute-EUA [22]h a s
been used. Grade refers to the severity of the AE. The
CTCAEv3.0employsgradesfrom1to5,withuniqueclinical
descriptions of severity for each AE based on the following
general guideline: grade 1, mild AE, grade 2, moderate AE,
grade 3, severe AE, grade 4, life-threatening or disabling AE,
and grade 5, death related to an AE. The adverse events were
judged in terms of clinical symptoms by interview at each
chemotherapy cycle with pharmaceutical. Serum clinical
chemistry, whole blood analysis, and leukocyte diﬀerential
counts were also used to monitor the eﬃcacy and toxicity by
physicians of the Department of Oncology.
2.13. Statistics. Data were analyzed using the EpiInfo com-
puter program, version 3.5.1 from the CDC, USA. The data
wereevaluatedusinganalysisofvariance(ANOVA)andt-test
andwereexpressedasamean ±SD.Whenthevarianceswere
nothomogenousandANOVAwasnotappropriate(Bartlett’s
P value < 0.05), Wilcoxon two-sample test was used to
evaluate the data. P<0.05 was considered statistically
signiﬁcant.
3. Results
The general characteristics of colorectal cancer patients
included in this study are shown in Table 1. The mean age
of the C group was 60.89 years, and the mean age of the UT
group was 62.68 years old.
One aim of the study was to evaluate the neutropenia,
thrombocytopenia, and anemia. The hemograms were ana-
lyzed each 15 days, and there were no signiﬁcant diﬀerences
in hematological parameters (Tables 2 and 3) between the
groups for any of the cycles examined. An important re-
duction in white blood cells (WBCs) count was observed in
both groups along the treatment. Unlike what was observed
in leukocytes, red blood cells (RBCs) showed recovery
of the hypochromic and microcytosis present at baseline.
Erythrocyte indices (mean corpuscular hemoglobin-MCH;
mean corpuscular volume, MCV) improved in both groups,
reaching normal values.
ThegenerationofROSmaydamagealltypesofbiological
molecules. Oxidative damages to lipids, proteins, or DNA
were evaluated by TBARS levels, protein carbonyl levels,
Table 1: General data of the CRC patients in adjuvant/palliative
chemotherapy (FOLFOX4) without Uncaria tomentosa supply (C
group) or receiving 300mg/day of Uncaria tomentosa (UT group).
Parameters Cg r o u p
n = 23
UT group
n = 20
aStates T
T1 0 1
T2 1 1
T3 16 12
T4 6 6
aStates N
N0 1 2
N1 8 8
N2 11 10
aStates M M0 13 17
M1 10 3
Age
<50 4 2
51–65 10 12
66–80 9 6
Gender Female 16 10
Male 7 10
Smoke
Smokers 2 0
ex-smokers 8 10
no smokers 13 10
Associated
chronic
diseases
Without 5 4
Hypertension 6 6
Hypertension + coronary
diseases/dyslipidemia/diabetes 37
Diabetes 2 2
Others 4 1
aStage of disease currently described by TNM, as published by the American
Joint Committee on Cancer (AJCC) and American Cancer Society (ACS).
and comet assay, respectively. Antioxidant defense system
was measured by activity of antioxidants enzymes catalase
and SOD. The Ut supplementation did not change oxidative
stressvaluesoractivityoftheantioxidantenzymes.Similarly,
the comet assay, a sensitive technique for the detection of
DNA damage at the level of the individual eukaryotic cell,
demonstrated no diﬀerences between groups (Table 4).
The CD4+ T cells and CD8+ T cells (absolute count
and ratio) used for the evaluation of the immune status
of CRC patients were not statistically diﬀerent following
Ut supplementation (Table 5) or chemotherapy (before
treatment began versus after the sixth FOLFOX4 cycle). The
UT and C groups showed diﬀerences before chemotherapy
in IL-6 levels, but such diﬀerences did not change over the
course of treatment. Moreover, in the comet assays, IL-6
levels showed large variations between subjects.
The assessment of adverse events (AEs) related to treat-
mentwasconductedbyinterviewingthepatientsduringeach
cycle of chemotherapy and through analysis of laboratory
tests and observation of abnormal symptoms presented by
patients. AEs were classiﬁed according to the Common
Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0)
[22]. Since there were no diﬀerences between groups, data4 Evidence-Based Complementary and Alternative Medicine
Table 2: Evaluation of hemoglobin, and erythrocyte indices of the CRC patients, during six cycles of adjuvant/palliative chemotherapy,
without Uncaria tomentosa supply (C group) or receiving 300mg/day of Uncaria tomentosa (UT group).
Parameters Group
Chemotherapy cycle
012345 6
Hb UT 123.5 125.2 127.2 123.5 125.3 121.4 118.6
g/L (14.9) (17.9) (17.0) (14.2) (13.9) (11.1) (10.4)
C 113.7 115.1 113.3 113.9 114.9 117.0 113.7
(17.6) (13.8) (15.7) (17.2) (14.2) (12.5) (14.2)
MCH UT 27.53 27.88 28.37 28.95 29.66 29.69 30.60∗
pg (1.99) (1.69) (1.97) (2.20) (2.31) (1.92) (2.16)
C 26.62 27.02 27.37 27.70 27.93 28.80 29.19∗
(2.61) (2.63) (2.59) (2.67) (2.63) (2.60) (2.44)
MCV UT 84.62 85.31 86.03 87.57 89.13 90.00 91.50∗∗
fL (4.31) (3.91) (3.65) (5.36) (5.59) (4.90) (4.84)
C 81.94 82.53 83.74 85.28 86.27 88.29 89.22∗∗
(6.8) (6.58) (6.4) (6.34) (6.02) (5.92) (5.51)
Values expressed as mean (SD). Hb: hemoglobin, MCH: mean corpuscular hemoglobin, MCV: mean corpuscular volume. UT group: patients treated with
FOLFOX4 + Uncaria tomentosa 300mg/day (n = 20), C group: patients treated with FOLFOX4 (n = 23); ∗P<0.05; ∗∗P<0.001; ∗∗∗P<0.0001 in relation
to the day 0.
Table 3: White blood cells count and platelets’s evaluation of the CRC patients in adjuvant/palliative chemotherapy, without Uncaria
tomentosa supply (C group) or receiving 300mg/day of Uncaria tomentosa (UT group).
Parameters Groups
Chemotherapy cycles
01 2 3 4 5 6
WBC UT 8.178 5.689∗ 5.184∗∗ 4.778∗∗ 4.956∗∗ 4.660∗∗ 4.442∗∗
cells ×109/L (2.705) (1.919) (2.051) (2.022) (2.006) (2.095) (2.433)
C 7.668 5.933∗ 5.391∗ 4.886∗ 4.473∗∗∗ 4.962∗∗ 4.195∗∗∗
(2.892) (2.137) (2.451) (2.039) (2.086) (2.157) (1.558)
Neutrophils UT 5.345 3.069∗ 2.600∗∗ 2.441∗∗ 2.429∗∗ 2.227∗∗ 2.343∗∗∗
cells ×109/L (2.691) (1.455) (1.411) (1.401) (1.456) (1.506) (1.842)
C 4.871 3.285∗ 2.848∗∗ 2.295∗∗∗ 2.190∗∗∗ 2.514∗ 1.975∗∗∗
(2.674) (1.618) (1.858) (2.295) (1.628) (1.797) (1.186)
Lymphocytes UT 2.038 1.888 1.859 1.673 1.776 1.728 1.433∗
cells ×109/L (.735) (.681) (.656) (.642) (.661) (.754) (.504)
C 1.901 1.888 1.815 1.769 1.650 1.697 1.578
(.702) (.737) (.717) (.827) (.648) (.531) (.659)
Monocytes UT .538 .515 .528 .482 .546 .547 .542
cells ×109/L (.215) (.157) (.197) (.216) (.244) (.241) (.306)
C .542 .533 .570 .602 .470 .595 .498
(.245) (.254) (.254) (.272) (.197) (.262) (.231)
Platelets UT 263 188∗ 174∗ 146∗∗∗ 135∗∗∗ 117∗∗∗ 117∗∗∗
count ×109/L (92) (43) (55) (48) (51) (42 ) (33)
C 286 216∗ 197∗∗ 161∗∗∗ 149∗∗∗ 165∗∗∗ 141∗∗∗
(76) (68) (64) (70 ) (66) (57) (58)
Values expressed as mean (SD). UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300mg/daily (n = 20); C group: CRC patients received
FOLFOX4 (n = 23); ∗P<0.05; ∗∗P<0.001; ∗∗∗P<0.0001 in relation to the day 0.
shows that Ut supplementation did not alter the occurrence
of AEs, related to chemotherapy, neither caused AE. The
most frequently observed AE in both groups were fatigue,
nausea, and a decrease in hematological parameters (Tables
6 and 7). An important reduction in neutrophils (grade
3 or 4) occurred in 25.4% of patients. Toxicity of the
Ut was also evaluated using liver, kidney, metabolic, and
constitutive parameters. Treatment with Ut did not alter
liver function, deﬁned as elevation of liver enzymes (alanine
aminotransferase-ALT, aspartate aminotransferase-AST, γEvidence-Based Complementary and Alternative Medicine 5
Table 4: Evaluation of lipid peroxidation, carbonylation of serum protein, DNA damage and antioxidant defenses of the CRC patients in
adjuvant/palliative chemotherapy (FOLFOX4), without Uncaria tomentosa supply (C group) or receiving 300mg/day of Uncaria tomentosa
(UT group).
Parameters Group
Chemotherapy cycles
0 1 2 3456
TBARS nmol UT 16.7 16.2 18.3 17.9 17.7 17.8 21.6
MDA/mL (9.34) (7.1) (7.2) (6.9) (4.1) (3.4) (11.8)
C 22.5 18.8 17.8 19.4 21.2 22.4 22.9
(11.6) (10.9) (11.3) (10.5) (8.9) (9.7) (10.5)
Protein carbonyl UT 0.63 0.56 0.61 0.61 0.68 0.67 0.6
nmol/mg protein (0.2) (0.2) (0.17) (0.18) (0.26) (0.2) (0.2)
C 0.79 0.77 0.73 0.72 0.78 0.9 0.84
(0.37) (0.4) (0.39) (0.36) (0.37) (0.43) (0.37)
Comet assay UT 29.04 26.78
Index damage (34.18) (31.99)
C 26.94 34.66
(49.3) (46.63)
Catalase UT 7.85 8.2 7.65 9.12 8.97 9.33 10.39
pmol/mg protein (3.3) (3.0) (2.81) (4.75) (4.71) (3.27) (4.08)
C 9.05 8.29 8.51 8.06 9.07 8.31 9.38
(4.9) (2.7) (4.05) (3.51) (3.71) (3.07) (3.78)
SOD UT 1.82 1.85 1.95 2.19 1.95 2.29∗ 2.41∗
U/mg protein (0.5) (0.44) (0.44) (0.43) (0.43) (0.44) (0.56)
C 1.91 1.91 2.1 2.15 2.09 2.12 2.13
(0.8) (0.76) (0.71) (0.78) (0.7) (0.81) (0.72)
Data expressed in mean (SD). TBARS, thiobarbituric acid-reactive substances; SOD, superoxide dismutase; UT group: patients treated with FOLFOX4 +
Uncaria tomentosa 300mg/daily (n = 20); C group: CRC patients received FOLFOX4 (n = 23). ∗P<0.05 in relation to the day 0.
Table 5: Immune status of CRC patients before treatment began and after 6 cycles of adjuvant/palliative chemotherapy (FOLFOX4) without
Uncaria tomentosa supply (C group) or receiving 300mg/day of Uncaria tomentosa (UT group).
Parameters Group Chemotherapy cycles
06
CD4+ T Cells UT 958.36 (414.6) 720.28 (271.72)
Cells/μL C 828.45 (431.25) 848.38 (430.56)
CD8+ T cells UT 494.0 (231.28) 390.64 (223.62)
Cells/μL C 490.29 (271.14) 394.27 (149.96)
CD4+ T/CD8+ TR a t i o UT 2.17 (0.76) 2.21 (0.78)
C 1.96 (1.03) 2.30 (1.08)
IL6 UT 4.07# (6.54) 5.1# (6.12)
ng/mL C 12.97 (13.28) 16.66 (18.2)
Data expressed as mean (SD); UT group: patients treated with FOLFOX4 + Uncaria tomentosa 300mg/daily (n = 20); C group: CRC patients received
FOLFOX4 (n = 23). #P<0.05 between groups.
glutamyl transpeptidase-GGT), and bilirubin levels, and
kidney function is evaluated by dosage of urea, metabolic
parameters (albumin levels and glycemia), and constitutive
parameters (weight loss) (data not shown). There was a
small diﬀerence in creatinine levels between groups before
treatment (UT = 74.25μmol/L, C = 68.95μmol/L), which
remained at the sixth cycle of treatment (UT = 76.90μmol/L,
C = 60.12μmol/L).
4. Discussion
Complementary and alternative medicine (CAM) has been
used by a large number of cancer patients worldwide.
Cultural, socioeconomic, and spiritual diﬀerences aﬀect the
rate of use. For instance, there are high rates of use in Mexico
(97.2%) and China (97%) [23, 24], an intermediate rate
of use in the USA (63%) [25], and lower rates of use in
Canada (47%) [26] and Iran (35%) [27]. The herbal remedy6 Evidence-Based Complementary and Alternative Medicine
Table 6: Frequency of side eﬀects reported by CRC patients in adjuvant/palliative chemotherapy in interview at ﬁrst and sixth cycle of the
treatment.
After 1 chemotherapy cycle After 6 chemotherapy cycles
Not present rarely sometimes often Always Not present Rarely Sometimes Often always
Fatigue 60.5 13.2 13.2 5.3 7.9 54.3 5.7 22.9 5.7 11.4
Insomnia 86.8 2.6 7.9 2.6 0 97.1 2.9 0 0 0
Vomiting 78.9 10.5 10.5 0 0 100 0 0 0 0
nausea 60.5 15.8 21.1 2.6 0 80.0 15.0 0 0 5.0
Dry skin 91.2 2.9 2.9 2.9 0 88.6 0 0 5.7 5.7
Pruritus/itching 81.6 2.6 10.5 0 5.3 91.4 5.7 0 0 2.9
Fever 97.4 2.6 0 0 0 97.1 2.9 0 0 0
Data expressed as % of the patients who had symptoms.
Table 7: Adverse events observed in CRC patients in adjuvant/palliative chemotherapy with FOLFOX4 (n = 43).
After 1 chemotherapy cycle (FOLFOX4) After 6 chemotherapy cycles (FOLFOX4)
G r a d er e f e r st ot h es e v e r i t yo ft h eA E ∗ Grade refers to the severity of the AE
0123401234
Hemoglobin 82.9 12.2 4.9 0 0 76.9 17.9 2.6 0 0
Leukocytes (total WBC) 97.6 2.4 0 0 0 74.4 5.1 15.4 5.1 0
Neutrophils/granulocytes 85.4 7.3 0 4.9 2.4 48.7 12.8 10.3 17.9 7.7
Lymphocytes 95.1 0 4.9 0 0 92.3 0 7.7 0 0
Platelets 97.6 0 2.4 0 0 84.6 10.3 5.1 0 0
Weight loss 82.9 9.8 2.4 4.9 0 92.3 0 2.6 5.1 0
Hyperglycemia 97.6 0 0 2.4 0 87.2 0 7.7 5.1 0
γ-glutamyl transpeptidase 100 0 0 0 0 89.8 10.2 0 0 0
Alkaline phosphatase 100 0 0 0 0 84.6 15.4 0 0 0
Neuropathy: sensory 100 0 0 0 0 94,9 0 5.1 0 0
Infection with Grade 3 or 4 neutrophils 100 0 0 0 0 97.4 0 2.6 0 0
Diarrhea 100 x 0 0 0 92.3 x 7.7 0 0
Values expressed as % of the patients who had AE. ∗Grade refers to the severity of the AE: grade 1 = mild AE; grade 2 = moderate AE; grade 3 = severe AE;
grade 4 = life-threatening or disabling AE; grade 5 = death related to an AE [22].
cat’s claw is used as CAM by some cancer patients. It is
thought to be an anticarcinogen, an immunostimulant, and
an antioxidant that can stimulate DNA repair. Despite a
theoretical understanding of its mechanism of action, the
evidence for its clinical eﬀectiveness is minimal [28].
To evaluate the eﬀectiveness of Ut in minimizing the
main side eﬀects of chemotherapy, a decrease in neu-
trophil and platelet counts, hemograms were analyzed
before each FOLFOX4 cycle (at an interval of 15 days).
Treatment with Ut was suspended on the days that patients
received chemotherapy, because some antineoplastic drugs
and CAMs are metabolized through the cytochrome P450
family, and an interaction could alter the metabolism of
patients [28]. Treatment with Ut did not improve the WBC,
RBC, or platelet counts, because there were no diﬀerences
between groups (UT versus C). In vivo assays in rats
undergoing chemotherapy demonstrated that neutrophils
recover signiﬁcantly sooner with Ut supplementation [14].
This eﬀect of Ut on WBC is due both to the stimulation
of myeloid precursors [12] and the eﬀect on ROS, which
increases survival of lymphocytes [29] and inhibits myeloid
cell diﬀerentiation [2]. We did not ﬁnd other clinical trials
with CRC patients using Ut. In a human volunteer study,
Ut extract was given at 250 or 350mg/day for 8 consecutive
weeks to healthy adult. There were no statistically signiﬁcant
diﬀerences among the groups in WBC [11]. Our group
conducted a clinical trial of women with breast cancer
undergoing chemotherapy treatment who received 300mg
of Ut daily. In this study, we found signiﬁcant diﬀerences
between the group that received Ut and the control group;
the Ut group showed higher neutrophils counts compared
with the control group (unpublished data). The diﬀerences
in the drugs used in the treatment of breast cancer (5-FU,
adriamycin, and cyclophosphamide) versus CRC (5-FU and
oxaliplatin) have to be considered, as do the diﬀerences in
time between cycles of chemotherapy (21 versus 15 days).
We must also consider the fact that all CRC patients in the
present study underwent colectomy, which could interfere
with the absorption of Ut.
Many previous studies have clearly shown the potential
oftheantioxidantUt,anditspotentradicalscavengeractivity
was conﬁrmed by several assays including the following: theEvidence-Based Complementary and Alternative Medicine 7
capacity to reduce the free radical diphenylpycrilhydrazyl
(DPPH assay) [30, 31], the reaction with the superoxide ani-
on, peroxyl [30], and hydroxyl radicals [30]a sw e l la sw i t h
the oxidant species, hydrogen peroxide, and hypochlorous
acid[30,32],andtheTEACassay[10].Theantioxidantactiv-
ity of Ut extracts was further assayed through determination
of TBARS production (using rat liver homogenates and
sarcoplasmic reticulum membranes) and by the inhibition
of free radical-mediated DNA-sugar damage [30, 33]. These
assays were primarily in vitro tests with one in vivo test [31].
Despitethisstrongevidence,nodiﬀerencesinoxidativestress
were found between groups that received or did not receive
Ut, as assessed by lipid peroxidation (TBARS) and protein
carbonyls. In addition, no diﬀerences were observed in the
antioxidant enzymes SOD or catalase.
There are close correlations between DNA damage, DNA
repair, and immune responses in lymphocytes. DNA damage
and mutations may result in a failure of T cells to proliferate
and undergo extensive clonal expansion upon antigenic
stimulation. Sheng et al. [11] showed that a water-soluble
extract of Ut caused a signiﬁcant decrease in DNA damage
and a concomitant increase in DNA repair in volunteers.
However, in our study, the comet assay did not demonstrate
a signiﬁcant diﬀerence in the group that received Ut. Ut
extract was prepared through an extraction of ground bark
with 70% ethanol. This process altered the composition of
the extract (oxindole alkaloids) compared with an aqueous
extract (like that used by Sheng et al. [11]). However, more
recently, water-soluble cat’s claw extract was shown not to
contain signiﬁcant amounts of alkaloids (<0.05%). Yet, it
was still shown to be eﬃcacious, because quinic acid is the
major active ingredient [34]. Further study is needed to
assess whether diﬀerences in the content of the extracts are
correlated with the diﬀerences in observed results.
Similar to oxidative stress, Ut did not show an eﬀect
on the analyzed immunologic parameters, the CD4+ Tc e l l -
CD8+ T cell count and the IL-6 levels despite the in vitro
evidence [35].
There were no drug-related toxic eﬀects observed for Ut
extract at a repeated dose of 300mg/day for 12 consecutive
weeks (Unha de Gato Herbarium), when judged in terms
of clinical symptoms, serum clinical chemistry, whole blood
analysis, and leukocyte diﬀerential counts. Similar results
have been shown in previous studies with volunteers [11,
36]. National Center for Complementary and Alternative
Medicine (USA) [37]h a sr e p o r t e df e ws i d ee ﬀects from cat’s
claw at the recommended dosages. Though rare, side eﬀects
may include headaches, dizziness, and vomiting.
Adverse events related to antineoplastic drugs (oxali-
platin and 5FU) are well known [1] and are similar to those
observed in our study.
5. Conclusion
Ut atdose300mgdryextractdailyisnoteﬀectiveinreducing
the most prevalent adverse events due to treatment with
5FU/Leucovorin and oxaliplatin in patients with advanced
CRC. No toxic eﬀects related to Ut were observed in the
group that received 300mg dry extract daily for 12 weeks.
Additional studies are needed to evaluate under which
conditions,drugs,ortypesofcancerUt mighthaveapositive
eﬀecton treatment,in decreasing neutropenia and thrombo-
cytopenia, or in improving the immune response.
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